Envista (NVST) Q3 2024 earnings summary

Executive summary

• Q3 2024 sales were $601.0 million, with core sales declining 5.3% year-over-year and underlying performance consistent with Q2.

• Net income for Q3 2024 was $8.2 million ($0.05 per diluted share), down from $21.5 million in Q3 2023, with significant nine-month losses due to $1.15 billion in impairment charges.

• Adjusted EBITDA for Q3 2024 was $54.9 million (9.1% margin), down from $123.5 million (19.6% margin) in Q3 2023.

• Share gains achieved in orthodontics and diagnostics, while consumables held share and implants undergrew the market, though the gap narrowed.

• Management is focusing on accelerating growth, operational improvement, and advancing company culture.

Financial highlights

• Q3 2024 revenue was $601.0 million, down from $631.3 million year-over-year; core sales declined 5.3%.

• Adjusted gross margin was 52.8%, down from 57.7% in Q3 2023.

• Adjusted diluted EPS was $0.12, compared to $0.43 in Q3 2023.

• Free cash flow for Q3 was $63.3 million (vs. $77.1 million prior year); year-to-date free cash flow was $179 million, up 45%.

• Cash and cash equivalents at quarter-end were $991.3 million, with $212.6 million in the U.S. and $778.7 million held internationally.

Outlook and guidance

• Full-year 2024 guidance reaffirmed: core sales growth of -1% to -4% and adjusted EBITDA margin of 10% to 12%.

• Q4 expected to return to reported growth as Spark revenue deferral impact lessens.

• Management expects continued headwinds from global economic conditions, inflation, and supply chain disruptions.

• Currency fluctuations and pricing controls in certain markets, such as China, are expected to impact future results.

• No material impact anticipated from the global minimum tax provisions in 2024.